| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 399.217 | 283.577 | 266.333 | 165.620 | 298.146 | 293.218 | 270.187 | 143.323 | 177.449 | 189.811 |
| Total Income - EUR | 400.644 | 284.880 | 267.002 | 166.030 | 299.879 | 294.168 | 270.749 | 143.865 | 177.855 | 191.962 |
| Total Expenses - EUR | 244.594 | 221.827 | 182.214 | 125.584 | 199.753 | 171.120 | 173.430 | 118.768 | 123.036 | 136.087 |
| Gross Profit/Loss - EUR | 156.050 | 63.053 | 84.788 | 40.446 | 100.126 | 123.048 | 97.319 | 25.097 | 54.818 | 55.875 |
| Net Profit/Loss - EUR | 129.401 | 52.265 | 82.170 | 38.787 | 97.128 | 120.297 | 94.667 | 23.688 | 53.076 | 50.713 |
| Employees | 7 | 8 | 9 | 8 | 7 | 7 | 6 | 5 | 5 | 6 |
Check the financial reports for the company - Med Nicon S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 1.580 | 36.192 | 30.568 | 22.791 | 13.579 | 5.027 | 751 | 891 | 1.458 | 1.780 |
| Current Assets | 269.273 | 78.118 | 113.689 | 68.036 | 148.729 | 184.938 | 149.337 | 77.247 | 95.299 | 103.589 |
| Inventories | 0 | 0 | 6.718 | 8.866 | 2.727 | 17.306 | 37.501 | 21.868 | 23.191 | 16.256 |
| Receivables | 91.139 | 8.236 | 42.959 | 17.474 | 41.154 | 68.579 | 18.640 | 26.373 | 39.970 | 48.896 |
| Cash | 178.134 | 69.882 | 64.012 | 41.695 | 104.847 | 99.053 | 93.195 | 29.006 | 32.138 | 38.437 |
| Shareholders Funds | 199.932 | 90.613 | 119.870 | 75.794 | 133.420 | 155.900 | 129.481 | 58.609 | 87.892 | 85.334 |
| Social Capital | 748 | 740 | 727 | 714 | 700 | 687 | 672 | 674 | 672 | 668 |
| Debts | 70.921 | 23.697 | 24.387 | 15.032 | 28.889 | 34.065 | 20.607 | 19.530 | 9.018 | 20.035 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "3250 - 3250" | |||||||||
| CAEN Financial Year |
3250
|
|||||||||
Comments - Med Nicon S.r.l.